Experimental Design Approach in HPLC Method Development: Application for the Simultaneous Determination of Sacubitril and Valsartan in Presence of Their Impurities and Investigation of Degradation Kinetics-Reference-Cited by-同舟云学术

Experimental Design Approach in HPLC Method Development: Application for the Simultaneous Determination of Sacubitril and Valsartan in Presence of Their Impurities and Investigation of Degradation Kinetics

Published:2017-11-18 Issue:1 Volume:81 Page:139-156
ISSN:0009-5893
Container-title:Chromatographia
language:en
Short-container-title:Chromatographia

Author:

Moussa Bahia A.,Hashem Hanaa M. A.,Mahrouse Marianne A.^ORCID,Mahmoud Sally T.

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,Clinical Biochemistry,Biochemistry,Analytical Chemistry

Link

http://link.springer.com/article/10.1007/s10337-017-3425-9/fulltext.html

Reference28 articles.

1. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380(9851):1387–1395. doi: 10.1016/S0140-6736(12)61227-6

2. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual acting angiotensin receptor—neprilysin inhibitor (ARNi). J Clin Pharmcol 50(4):401–414. doi: 10.1177/0091270009343932

3. de Bold AJ (2011) Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. Can J Physiol Pharm 89(8):527–531. doi: 10.1139/y11-019

4. Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, Akahori M, Zhang J (2015) Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res 38(4):269–275. doi: 10.1038/hr.2015.1

5. Thürmann PA (2000) Valsartan: a novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 1(2):337–350. doi: 10.1517/14656566.1.2.337

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tri-chromic sustainable tools of derivative/discrete Fourier transform HPLC convoluted peaks: Application on LCZ696, an antihypertensive supramolecular complex, with its in process and degradation impurity analysis;Microchemical Journal;2024-05

2. Development of RP-HPLC–UV Technique for “N,N’-Disubstituted Terephthalamides”, the Depolymerized End Products of Polyethylene Terephthalate Waste;Chromatographia;2024-02-20

3. Ecological assessment and development of analytical methods for concurrent quantification of valsartan and sacubitril: whiteness comparative study based on relative scoring;RSC Advances;2024

4. Sustainability Appraisal of Developed Analytical Methods for Concurrent Determination of Valsartan and Sacubitril Using AES, GAPI, AGREE Metric and RGB 12 Algorithm Approaches: Whiteness Comparative Study Based on Relative Scoring;2024

5. An innovative combination of Box-Behnken design and ecofriendly approaches for the simultaneous determination of aspirin, clopidogrel, atorvastatin and rosuvastatin in their fixed-dose combination tablets;BMC Chemistry;2023-11-24